Kiran K Khush1, Hannah A Valantine. 1. Stanford University School of Medicine, Division of Cardiovascular Medicine, Stanford, CA 94305, USA. kkhush@cvmed.stanford.edu
Abstract
BACKGROUND: Heart transplantation is a well-established therapeutic option for many patients with end-stage heart disease. A major challenge in heart transplantation today is providing effective immunosuppression to prevent graft rejection while minimizing the many adverse effects of currently available therapies. OBJECTIVE: To systematically review current immunosuppressive treatment strategies after heart transplantation and to review emerging drugs in various stages of development. METHODS: A comprehensive literature review was performed using the online PubMed and Pharmaprojects databases. RESULTS/ CONCLUSIONS: This article gives an overview of the immunosuppressive agents in current use, with a detailed review of emerging drugs with novel therapeutic targets.
BACKGROUND: Heart transplantation is a well-established therapeutic option for many patients with end-stage heart disease. A major challenge in heart transplantation today is providing effective immunosuppression to prevent graft rejection while minimizing the many adverse effects of currently available therapies. OBJECTIVE: To systematically review current immunosuppressive treatment strategies after heart transplantation and to review emerging drugs in various stages of development. METHODS: A comprehensive literature review was performed using the online PubMed and Pharmaprojects databases. RESULTS/ CONCLUSIONS: This article gives an overview of the immunosuppressive agents in current use, with a detailed review of emerging drugs with novel therapeutic targets.
Authors: Shoba Amarnath; Hao Chen; Jason E Foley; Carliann M Costanzo; Joel D Sennesh; Michael A Solomon; Daniel H Fowler Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240